Hologic, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
6.1
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
HOLX
Clean balance sheet with low leverage (0.5× debt-to-equity).
⚠ cautious analyst consensus — few Buy ratings.
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
HOLD
Target $76.67 (+0.9%)
9 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
HOLX
PFE
31.5×
Trailing P/E
19.4×
15.6×
Forward P/E
9.4×
13.2%
Profit Margin
12.4%
60.4%
Gross Margin
75.8%
10.9%
ROE
8.9%
2.5%
Revenue Growth
-1.2%
-9.2%
Earnings Growth
—
0.70
Beta
0.39
—
Price / Book
—
$17.0B
Market Cap
$149.8B
$52 – $76
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →